Cartesian SEC Filings

RNAC filed a Rule 144 notice for an insider stock sale. Christopher M. Jewell plans to sell 1,510 shares of RNAC common stock through Morgan Stanley Smith Barney on or about 01/09/2026 on the NASDAQ market. The planned sale has an aggregate market value of $12,105.37, based on the price at the time of the notice, and is against a backdrop of 26,003,606 common shares outstanding.

The 1,510 shares to be sold were acquired on 01/02/2026 through the vesting of restricted stock under a registered plan, in exchange for services rendered to the company. The notice also reports that Jewell previously sold 17,935 common shares on 11/19/2025, generating gross proceeds of $129,587.55.

Cartesian Therapeutics, Inc. filed a current report to furnish new investor materials. The company is making available a corporate slide presentation it uses at industry and investor conferences, attached as Exhibit 99.1, which provides updates and summaries of its business.

The company also issued a press release on January 9, 2026 highlighting recent progress and outlining its 2026 outlook, attached as Exhibit 99.2. These materials are furnished under Regulation FD, not deemed “filed” for liability purposes, and are not incorporated into other securities law filings unless specifically referenced.

Cartesian Therapeutics President and CEO Carsten Brunn reported a sale of company common stock. On 01/06/2026, he sold 23,766 shares of Cartesian Therapeutics, Inc. (RNAC) common stock at a price of $6.8197 per share.

According to the footnote, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. After this transaction, Brunn directly beneficially owned 323,530 shares of Cartesian Therapeutics common stock.

Cartesian Therapeutics Chief Medical Officer Milos Miljkovic reported a small sale of company stock tied to equity compensation taxes. On 01/06/2026, he sold 3,573 shares of Cartesian Therapeutics, Inc. common stock at a price of $6.8197 per share. According to the footnote, the shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees, rather than as a discretionary open-market sale. After this transaction, he continued to beneficially own 58,820 shares of common stock in direct ownership.

Cartesian Therapeutics, Inc. reported an insider transaction by its Chief Financial Officer, Blaine Davis. On 01/06/2026, Davis sold 10,591 shares of the company’s common stock at an average price of $6.8197 per share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees, indicating a tax-related sale rather than a discretionary open-market reduction in holdings. Following this transaction, Davis beneficially owned 121,220 shares of Cartesian Therapeutics common stock directly.

Cartesian Therapeutics director Patrick Zenner reported new equity awards. On January 2, 2026, he acquired 2,600 shares of common stock at a price of $0, representing restricted stock units that will vest in full on January 2, 2027. On the same date, he was granted a stock option for 7,800 shares of common stock at an exercise price of $6.76 per share, first exercisable on January 2, 2027 and expiring on January 1, 2036. After these transactions, he directly beneficially owned 12,974 shares of common stock and 7,800 stock options.

Cartesian Therapeutics Chief Operations Officer Emily English reported new equity awards in the company’s stock. On January 2, 2026, she received 24,000 shares of common stock at a price of $0, bringing her directly owned common stock holdings to 94,226 shares.

On the same date, she was granted an employee stock option for 71,000 shares of common stock at an exercise price of $6.76 per share, expiring on January 1, 2036. The restricted stock units vest 25% on January 2, 2027, with the rest vesting in three equal annual installments through January 2, 2030, while the option vests 25% on January 2, 2027, and the remaining 75% in 36 equal monthly installments thereafter.

Cartesian Therapeutics director Michael Singer reported new equity awards from the company, including 7,800 stock options and 2,600 restricted stock units granted on January 2, 2026. The stock options give him the right to buy 7,800 shares of common stock at $6.76 per share, become exercisable on January 2, 2027, and expire on January 1, 2036. The restricted stock units represent contingent rights to receive 2,600 shares of common stock that will vest in full on January 2, 2027. Following these awards, he directly holds 56,133 common shares and has additional indirect holdings through several trusts, his spouse, and custodial accounts for his children.

Cartesian Therapeutics, Inc. director and 10% owner Timothy A. Springer reported new equity awards. On January 2, 2026, he received 2,600 shares of common stock at a price of $0 through restricted stock units that will vest in full on January 2, 2027. He was also granted a stock option for 7,800 shares of common stock at an exercise price of $6.76 per share, exercisable starting January 2, 2027 and expiring January 1, 2036. Following these awards, he directly beneficially owned 8,646,285 shares of common stock, with additional indirect holdings of 330,695 shares by his wife and 656,513 shares held by TAS Partners LLC, for which he is managing member and disclaims beneficial ownership except to the extent of any pecuniary interest.